Has Kevin Clark received payments from drug or device companies?

Yes. Drug and device makers reported $4,979 in general payments to Kevin Clark across 90 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kevin Clark did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kevin Clark come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kevin Clark

Ophthalmology · Sewickley, PANPI 1447366976

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,487 of the $4,979 with a category attached, or 70.0%. 24 manufacturers reported payments, led by Alcon at 38.9% of the total. Reporting peaked in 2019 at $3,175 and has fallen 93.0% since, to $222 in 2025.

$4,979in general payments, 2019–2025

Across 90 payments — averaging $55.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Alcon$2K
AbbVie$628
Coopervision Inc.$511
Carl Zeiss Meditec, Inc.$344
Ivantis, Inc$245
Kestra Medical Technology Services, Inc.$222
plus $1K from 18 others

What the payments were for

Consulting fees$1503%
Speaking & faculty fees$51110%
Travel & lodging$83017%
Food & beverage$3,48770%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Alcon	22	$1,939
AbbVie(2 entities)	26	$628
Coopervision Inc.	1	$511
Carl Zeiss Meditec, Inc.	2	$344
Ivantis, Inc	5	$245
Kestra Medical Technology Services, Inc.	3	$222
NEW World Medical,inc.	2	$185
Sun Pharmaceutical Industries Inc.	5	$136
Shire North American Group Inc	1	$111
Johnson & Johnson Surgical Vision, Inc.	1	$102
Biotissue Holdings Inc.	2	$85
Oyster Point Pharma, Inc.	3	$67
Carl Zeiss Meditec USA, Inc.	1	$60
Mallinckrodt Hospital Products Inc.	2	$58
Bausch & Lomb, A Division Of Bausch Health US, LLC	3	$52
Amgen	2	$47
Rxsight Inc	1	$41
Bausch & Lomb Americas Inc.	2	$35
Novartis	1	$23
Travere Therapeutics, Inc.	1	$21
Dompe US, Inc.	1	$20
ABB Con-cise Optical Group LLC	1	$18
Mallinckrodt Enterprises LLC	1	$16
Musculoskeletal Transplant Foundation Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,979 in reported general payments places this provider in the 80th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania →

Other ophthalmology in Sewickley

Julia HallerPhiladelphia$1.5M
Francis MahPittsburgh$1.1M
Brandon AyresBala Cynwyd$929K
David AlmeidaErie$734K
Carl RegilloPlymouth Meeting$721K
Robert NoeckerPittsburgh$632K
Beeran MeghparaPhiladelphia$496K
Michael KlufasPlymouth Meeting$393K
Jonathan MyersPhiladelphia$359K
Mark BlecherPhiladelphia$357K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →